Karius will expand access to its proprietary microbial cell-free DNA technology to help doctors diagnose infectious diseases, broaden clinical development, and accelerate technology innovation

Read more —>

Karius to present studies at ASM Microbe 2019 demonstrating clinical utility of the Karius Test, including ability to accurately detect pathogens in cases of endocarditis and immunocompromised patients

Read More —>

Karius, the leading U.S. infectious disease genomics company, announced today that the new version of its proprietary KariusTM Test can now quantify the abundance of pathogens detected. The test uses next-generation sequencing of microbial cell-free DNA (cfDNA) to identify over 1,000 pathogens from a single blood sample. Results are typically delivered the next day.

Reade More —>